Pubertal Development in
17Beta-Hydroxysteroid Dehydrogenase Type 3 Deficiency
.

17β-hydroxysteroid dehydrogenase (17β-HSD) type 3 deficiency is a rare genetic condition affecting testosterone production. Prior research has shown that this disorder leads to underandrogenisation in 46,XY individuals, often resulting in female sex assignment at birth. It was already known that testosterone synthesis is crucial for male pubertal development. However, uncertainty remained about the variability in pubertal outcomes among affected individuals. No prior work had resolved how residual enzyme activity might influence testosterone levels. This gap motivated further investigation into the genetic mutations and clinical manifestations. Researchers sought to understand how different mutations affect hormone values and gender assignment. The study aimed to clarify the potential for male pubertal development in these patients.

The study aimed to investigate pubertal development in 46,XY individuals with 17β-HSD type 3 deficiency. Researchers focused on the relationship between specific mutations, hormone levels, and clinical outcomes. The goal was to determine how genetic variations influence testosterone synthesis during puberty. This uncertainty drove the decision to analyze four patients with confirmed HSD17B3 mutations. The researchers wanted to assess whether residual enzyme activity could lead to male-typical pubertal changes. They also sought to evaluate the impact of early sex assignment on long-term outcomes. The study aimed to provide evidence for optimal gender assignment and intervention timing. These findings could help guide clinical decisions for similar cases.

The researchers analyzed four 46,XY patients diagnosed with 17β-HSD type 3 deficiency. They reviewed medical records, hormone values, and clinical observations during puberty. Genetic testing identified mutations in the HSD17B3 gene for each patient. The study compared patients with deleterious mutations to those with possible residual enzyme activity. Hormone levels were measured to assess testosterone production during puberty. Clinical findings included gender assignment at birth and pubertal development patterns. Researchers evaluated whether testosterone levels reached male reference ranges. The study used a case series approach to explore variability in outcomes.

Three patients were assigned a female sex at birth, and one was assigned a male sex. All had confirmed mutations in the HSD17B3 gene. Patients with deleterious mutations had lower testosterone levels at puberty than those with residual activity. One patient with residual activity developed male pubertal features. All four patients produced testosterone above 0.7 µg/L during puberty. This level was sufficient to induce variable androgenisation in each individual. Testosterone values in the male reference range were observed in some patients. These findings suggest that male pubertal development is possible in certain cases.

The authors propose that patients with residual 17β-HSD type 3 activity may achieve male pubertal development. Testosterone levels in the male reference range were observed in some cases. These findings suggest that male sex assignment may be appropriate for such patients. The study highlights variability in pubertal outcomes based on genetic mutations. Researchers suggest avoiding surgical interventions until patients can make informed decisions. The authors emphasize the importance of monitoring hormone levels during puberty. They propose that medical and surgical options should be considered together with patient preferences. These conclusions are based on the observed clinical and genetic data.